JP2020015733A - 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド - Google Patents

骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド Download PDF

Info

Publication number
JP2020015733A
JP2020015733A JP2019149672A JP2019149672A JP2020015733A JP 2020015733 A JP2020015733 A JP 2020015733A JP 2019149672 A JP2019149672 A JP 2019149672A JP 2019149672 A JP2019149672 A JP 2019149672A JP 2020015733 A JP2020015733 A JP 2020015733A
Authority
JP
Japan
Prior art keywords
fgfr3
polypeptide
sfgfr3
skeletal
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019149672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020015733A5 (enExample
Inventor
エルヴィール・グーズ
Gouze Elvire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Toulouse
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Toulouse III Paul Sabatier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Universite Toulouse III Paul Sabatier filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to JP2019149672A priority Critical patent/JP2020015733A/ja
Publication of JP2020015733A publication Critical patent/JP2020015733A/ja
Publication of JP2020015733A5 publication Critical patent/JP2020015733A5/ja
Pending legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2019149672A 2019-08-19 2019-08-19 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド Pending JP2020015733A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019149672A JP2020015733A (ja) 2019-08-19 2019-08-19 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019149672A JP2020015733A (ja) 2019-08-19 2019-08-19 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015553175A Division JP2016506914A (ja) 2013-01-16 2013-01-16 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド

Publications (2)

Publication Number Publication Date
JP2020015733A true JP2020015733A (ja) 2020-01-30
JP2020015733A5 JP2020015733A5 (enExample) 2020-09-10

Family

ID=69580027

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019149672A Pending JP2020015733A (ja) 2019-08-19 2019-08-19 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド

Country Status (1)

Country Link
JP (1) JP2020015733A (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110272900A (zh) * 2019-04-19 2019-09-24 中国人民解放军陆军军医大学 用于制备骨骼发育异常猪模型的sgRNA及其应用
WO2024194300A1 (en) * 2023-03-20 2024-09-26 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11508358A (ja) * 1995-06-12 1999-07-21 イエーダ リサーチ アンド ディベロップメント カンパニー，リミテッド 間葉性骨格前駆細胞についてのマーカーとしてのｆｇｆｒ３
WO2002102973A2 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
JP2003104908A (ja) * 2001-09-28 2003-04-09 Ichikazu Nakao 軟骨無形成症治療剤
US20030068313A1 (en) * 2001-09-28 2003-04-10 Kazuwa Nakao Therapeutic agents for achondroplasia
WO2004110487A1 (en) * 2003-06-17 2004-12-23 Prochon Biotech Ltd. Treatment of t cell mediated diseases by inhibition of fgfr3
WO2007014123A2 (en) * 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
JP2007526770A (ja) * 2004-02-24 2007-09-20 アラーガン、インコーポレイテッド ボツリヌス毒素スクリーニングアッセイ
WO2008133873A2 (en) * 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
WO2012088608A1 (en) * 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11508358A (ja) * 1995-06-12 1999-07-21 イエーダ リサーチ アンド ディベロップメント カンパニー，リミテッド 間葉性骨格前駆細胞についてのマーカーとしてのｆｇｆｒ３
WO2002102973A2 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
JP2005500034A (ja) * 2001-06-20 2005-01-06 プロション バイオテク リミテッド 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
JP2003104908A (ja) * 2001-09-28 2003-04-09 Ichikazu Nakao 軟骨無形成症治療剤
US20030068313A1 (en) * 2001-09-28 2003-04-10 Kazuwa Nakao Therapeutic agents for achondroplasia
WO2004110487A1 (en) * 2003-06-17 2004-12-23 Prochon Biotech Ltd. Treatment of t cell mediated diseases by inhibition of fgfr3
JP2007526770A (ja) * 2004-02-24 2007-09-20 アラーガン、インコーポレイテッド ボツリヌス毒素スクリーニングアッセイ
WO2007014123A2 (en) * 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
WO2008133873A2 (en) * 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
WO2012088608A1 (en) * 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARCHIVES DE PEDIATRIE, vol. 16, no. 6, JPN5016001787, 1 June 2009 (2009-06-01), pages 664 - 666, ISSN: 0004597203 *
BRITISH JOURNAL OF CANCER, vol. 89, no. 7, JPN5016001599, 2003, pages 1276 - 1284, ISSN: 0004371413 *
HUMAN MOLECULAR GENETICS, vol. 21, no. 26, JPN5016001597, December 2012 (2012-12-01), pages 5443 - 5455, ISSN: 0004371411 *
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 27, JPN5016001598, 2010, pages 20644 - 20653, ISSN: 0004371412 *
MOL. CELL BIOL. RES. COMMUN., vol. 4, JPN6019005430, 2001, pages 365 - 373, ISSN: 0004597204 *
PEDIATRIC RES., vol. 46, no. 4, JPN6020039309, 1999, pages 435 - 439, ISSN: 0004597205 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110272900A (zh) * 2019-04-19 2019-09-24 中国人民解放军陆军军医大学 用于制备骨骼发育异常猪模型的sgRNA及其应用
CN110272900B (zh) * 2019-04-19 2024-03-26 中国人民解放军陆军军医大学 用于制备骨骼发育异常猪模型的sgRNA及其应用
WO2024194300A1 (en) * 2023-03-20 2024-09-26 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia

Similar Documents

Publication Publication Date Title
US11702642B2 (en) Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
EP3308796B1 (en) Activin-actrii antagonists and uses for treating bone and other disorders
US20210009657A1 (en) Soluble fgfr3 decoys for treating skeletal growth disorders
JP2018500315A (ja) 組織石灰化の治療方法
US20200297799A1 (en) Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides
JP2020015733A (ja) 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
HK40039498A (en) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
HK1217959B (en) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
RU2794170C2 (ru) ЛЕЧЕНИЕ АНОМАЛЬНОГО ОТЛОЖЕНИЯ ВИСЦЕРАЛЬНОГО ЖИРА С ИСПОЛЬЗОВАНИЕМ РАСТВОРИМЫХ ПОЛИПЕПТИДОВ РЕЦЕПТОРА ФАКТОРА РОСТА ФИБРОБЛАСТОВ 3 (sFGFR3)
HK40050674A (en) Soluble fgfr3 decoys for treating skeletal growth disorders
HK1254086B (en) Activin-actrii antagonists and uses for treating bone and other disorders
HK1246313B (en) Soluble fgfr3 decoys for treating skeletal growth disorders
HK1214525B (en) Activin-actrii antagonists and uses for treating bone and other disorders

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210422

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210921